Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsMEX:VRTX 92 EV-to-EBITDA is 21.10 as of Jul. 22, 2026, which is 7% below its 10-year median of 22.79. GuruFocus rates MEX:VRTX with a GF Score™ of 92/100 and a GF Value™ of MXN8,906.66 (Fairly Valued). The stock has 5 warning signs investors should review. Among 398 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 65.83% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vertex Pharmaceuticals's enterprise value is MXN2,039,546 Mil.
Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN96,649 Mil. Therefore, Vertex Pharmaceuticals's EV-to-EBITDA for today is 21.10.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
MEX:VRTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1099.73 Med: 22.79 Max: 2085.27
Current: 22.18
During the past 13 years, the highest EV-to-EBITDA of Vertex Pharmaceuticals was 2085.27. The lowest was -1099.73. And the median was 22.79.
MEX:VRTX's EV-to-EBITDA is ranked worse than 65.83% of 398
companies
in the Biotechnology industry
Industry Median: 12.295
vs MEX:VRTX: 22.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vertex Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vertex Pharmaceuticals's share price for today is MXN8476.00.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN308.966.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, ALNY, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-EBITDA falls into.
Vertex Pharmaceuticals's current Enterprise Value is MXN2,039,546 Mil.
Vertex Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN96,649 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (MEX:VRTX) has a EV-to-EBITDA of 21.10 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vertex Pharmaceuticals. This is near median its historical median of 22.79. According to the industry distribution chart, Vertex Pharmaceuticals ranks #262 out of 398 companies in the Biotechnology industry, placing it in the top 65.8%.
Is Vertex Pharmaceuticals' EV-to-EBITDA too high?
Vertex Pharmaceuticals' current EV-to-EBITDA of 21.10 is near median its 10-year median of 22.79. The Biotechnology industry median EV-to-EBITDA is 12.30. Vertex Pharmaceuticals' value of 21.10 is 71.6% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #262 out of 398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' EV-to-EBITDA compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #262 out of 398 companies for EV-to-EBITDA. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.30. Vertex Pharmaceuticals' value of 21.10 is 71.6% above this benchmark. While the company's 10-year median is 22.79 vs. the industry median of 12.30, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.30, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current EV-to-EBITDA of 21.10 is 71.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vertex Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current EV-to-EBITDA is 21.10, which is near median its own 10-year median of 22.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,906.66, compared to a current price of MXN8,476.00 — trading 4.8% below its estimated fair value. The current EV-to-EBITDA is 21.10, which is near median its 10-year median of 22.79 and 71.6% above the Biotechnology industry median of 12.30. Vertex Pharmaceuticals' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current EV-to-EBITDA is 21.10 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,476.00 is trading 4.8% below its estimated GF Value™ of MXN8,906.66.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
EV-to-EBITDA: 21.10 (near median its 10-year median of 22.79)
GF Value™: MXN8,906.66 vs. price of MXN8,476.00 (4.8% below fair value)
Industry Position: 71.6% above the Biotechnology median (#262 of 398)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
92GF Score
Get the complete analysis for MEX:VRTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
